A series of N- {2-oxo-2-[4-(1,3-benzothiazol-2-yl)piperazin-1-yl]}-(het)arenecarboxamides 4a -l, sulfonamide derivatives 8a -i as well as benzothiazole-containing N 1 -(2-oxoethyl)-N 1 -arylthioureas 9a -c have been synthesized. Compounds 4a -l and 9a were evaluated, in vitro, for their antiproliferative activity against a large panel of human tumor-derived cell lines. Compounds 4l and 9a were the most potent analogs in this series, showing remarkable effects on human splenic B-lymphoblastoid cells (WIL-2NS) and human acute B-lymphoblastic leukemia (CCRF-SB) cell lines (4l: CC 50 = 5.1 and 7.3 µ M, respectively), and compound 5 against CCRF-SB cell lines with CC 50 = 2.3 µ M. These compounds are leading candidates for further development. Compounds 6 -7a -i were screened as inhibitors against HIV-1 and HIV-2, and no activity has been witnessed.
Introduction
Several benzothiadiazoles have shown selective antiproliferative activity, especially the phenyl-substituted benzothiazoles [1 -3] . Substituted 2-(4-aminophenyl)benzothiazoles were developed and comprised a novel class of antitumor-active compounds, especially against sensitive breast tumor cell lines, e. g., MCF-7 and MDA 468, and extended to certain colon, lung, melanoma, renal, and ovarian tumor cell lines [4 -7] . Pyrimidobenzothiazole and benzothiazoloquinoline derivatives [5] , imidazobenzothiazoles [8] , polymerized benzothiazoles [9, 10] as well as several derivatives of substituted benzothiazoles [11] showed remarkable antitumor activity against malignant cell lines.
Some (arylamino)benzothiazoles, such as 2-(4-amino-3-methylphenyl)-benzothiazole [12, 13] , 2-(4-aminophenyl)-benzothiazole [14, 15] , the fluoro analog (5F 203) [16 -19] and 2-(3,4-dimethoxyphenyl)-5-fluoro-benzothiazole (1) [20] are considered as potent ligands for the arylhydrocarbon receptor (AhR) which translocates with the drug to cell nuclei (Fig. 1) . A further class of benzothiazoles, e. g. 4-(benzothi-0932-0776 / 10 / 1100-1372 $ 06.00 c 2010 Verlag der Zeitschrift für Naturforschung, Tübingen · http://znaturforsch.com azol-2-yl)-4-hydroxycyclohexa-2,5-dienone [21] , have been synthesized and exhibited potent antitumor activity against renal and colon cancer cell lines with prodrug Phortress [22] , and human mammary tumor xenografs [23] , and is currently under pharmacological investigation in phase I clinical trial in the UK. Yoshida et al. [24] have synthesized a highly potent benzothiazole derivative bearing an amido substituent that displays excellent in vivo inhibitory effect on tumor growth. Recently, Racane et al. [25] have described the synthesis of bis-disubstituted amidinobenzothiazoles as potential anti-HIV agents.
In continuation of our research on the synthesis and biological evaluation of benzothiazole analogs [26 -29] , we report here the synthesis and antiproliferative and anti-HIV evaluation of new benzothiazole derivatives bearing 2-(piperazin-1-yl)-2-oxoethyl-benzamide, sulfonamide and thiourea functions. 
Results and Discussion

Synthesis
In the present work, amine 2, prepared previously in our laboratory, has been selected for the synthesis of new potentially active substituted amide derivatives. Two methods have been employed in the preparation of the corresponding amide derivatives from the reaction of 2 with the appropriate carboxylic acid 3a -l (Scheme 1). The first method includes the preparation of amides 4a -c, l (23 -38 % yield), by treatment of 2 with the benzoic acids 3a -c or 3-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-ylthio)propanoic [30] acid, using 1-hydroxybenzotriazole (HOBt) [31, 32] and N, N -dicyclohexylcarbodiimide (DCC) [33] as coupling reagents. The second method proceeded by preparation of the amides 4d -k in 57 -90 % yield, from treatment of 2 with the carboxylic acid chlorides 3d -k in the presence of Et 3 N.
The structures of the newly synthesized compounds 4a -k are in agreement with the 1 H NMR, 13 C NMR, and mass spectra. In the 1 H NMR spectra, the piperazine protons showed a similar pattern in the region δ = 4.10 -3.13 ppm for all compounds. The singlets in the region δ = 4.43 -3.94 ppm were assigned to CH 2 NH protons. The 13 C NMR spectra of 4a -l contained similar resonance signals for the piperazine and benzothiazole carbon atoms. CH 2 NH carbon signals were observed in the region δ = 41.9 -41.0 ppm. Compound 4l was selected for further NMR studies. In the gradient-selected HMBC spectrum [34] of 4l, the CH 2 NH methylene protons at δ H = 4.11 ppm showed a 3 J C,H coupling to the carbonyl carbon atom (C CH 2 CH 2 S = O, δ C = 169.1 ppm) as well as a 2 J C,H coupling to the carbonyl carbon atom C Npiperazine =O, (δ C = 166.0 ppm). Furthermore, the C CH 2 CH 2 S = O carbon atom showed two couplings: a 3 J C,H coupling with the CH 2 CH 2 S protons at δ H = 3.20 ppm, and a 2 J C,H coupling with the CH 2 CH 2 S protons at δ H = 2.55 ppm. C-4 of the imidazole moiety (δ C = 148.3 ppm) showed a 3 J C,H coupling to the CH 2 CH 2 S protons (δ H = 3.20 ppm). Next, our target was the synthesis of N-{2-oxo-2-[4-(1,3-benzothiazol-2-yl)piperazin-1-yl]}-(het)arenesulfonamides aiming to evaluate their HIV-inhibiting potential. Thus, the hydrazide 6 was prepared (84 %) by treatment of the ester 5 with hydrazine hydrate. Treatment of 6 with the arenesulfonyl chlorides 7a -i afforded the corresponding sulfonamides 8a -i in 39 -96 % yield (Scheme 2).
The structures of 6 and 8a -i were assigned on the basis of their 1 H NMR, 13 C NMR, and mass spectra. In the former the multiplets at higher field (δ = 8.56 -7.04 ppm) were attributed to the aryl protons. The methylene protons of the piperazine moiety appeared as multiplets in the region δ = 3.69 -2.42 ppm. The 13 C NMR spectra of 6 and 8a -i were fully assigned (cf. Experimental Section), while compound 8b was selected for a detailed 13 C NMR analysis. The spectrum showed signals at δ = 169.9 -167.9 ppm and δ = 168.5 -164.0 ppm which were assigned to C=N and C=O, respectively. The COCH 2 resonances were observed in the region δ = 60.8 -59.9 ppm, and the piperazine carbon atoms resonated in the regions δ = 53.3 -51.4 ppm and δ = 48.5 -47.2 ppm. The aromatic carbon atoms were observed in the region δ = 144.9 -114.5 ppm. Compounds 9a -c, combining a benzothiazole, a piperazinecarbonyl and a thiourea residue were also prepared. Thus, treatment of 2 with phenyl, 4-chloroor 4-methylphenyl isothiocyanate afforded the thiourea derivatives 9a -c in 61, 69, and 59 % yield, respectively (Scheme 3). The assignment of proton and carbon atoms of the benzothiazole and piperazine rings were deduced from comparison with those of 4a -k. The CH 2 NS protons resonated together with the piperazine protons in the region δ = 3.49 -3.31 ppm as multiplets. In the 13 C NMR spectra of 9a -c, the C=S carbon signals appeared at higher field (δ = 181.3, 181.6, and 180.0 ppm, respectively), while the resonances at δ = 167.5, 167.9, and 167.7 ppm were assigned to C 2 benzothiazol , respectively. C Npiperazine = O carbons appeared at δ = 164.3, 164.7, and 164.1 ppm, respectively, and C 4 benzothiazol carbons resonated at δ = 149.2, 149.0, and 149.1 ppm, respectively. The CH 2 NS carbon atoms appeared together with the piperazine carbons in the region δ = 48.5 -43.1 ppm. The signals of aromatic carbon atoms were assigned.
In vitro antiproliferative activity
Compounds 4a -l and 9a were selected for the antiproliferative activity screening and tested in vitro against a panel of tumor cell lines consisting of CD4 human T-cells containing integrated leukaemia, human acute T-lymphoblastic leukaemia (CCRF-CEM), and human splenic B-lymphoblastoid cells (WIL-2NS), human acute B-lymphoblastic leukaemia (CCRF-SB), human skin melanoma (SK-MEL-28), human breast adenocarcinoma (MCF-7), human lung squamous carcinoma (SK-MES-1), human hepatocellular carcinoma (Hep-G2), human prostate carcinoma (DU-145), human foreskin fibroblast (CRL7065), and human lung fibroblast (MRC-5). The microculture tetrazolium assay (MTT) method [35] was used for estimation of the in vitro tumor-inhibiting activity of the tested compounds. The cell lines of tumor subpanels were incubated within five concentrations (0.01 -100 mmol L −1 ) of each tested compound for 48 h. For comparative purposes, we evaluated the cytotoxic activities of the compounds relative to Doxorubicin. The compounds were dissolved in DMSO at 100 mmol L −1 and then diluted in culture.
All compounds were inactive except 4l which showed activity against human splenic B-lymphoblastoid cells (WIL-2NS) and human acute B-lymphoblastic leukemia (CCRF-SB) cell lines with CC 50 = 5.1 and 7.3 µ M, respectively. Compound 9a exhibited activity against CCRF-SB cell lines with CC 50 = 2.3 µ M.
In conclusion, introduction of a thiourea residue in the backbones of 9a generally enhanced the activity of the benzothiazole derivatives in comparison to the activity of other analogs 4a -l.
In vitro anti-HIV assay
Compounds 5 -8a -i were evaluated for their in vitro anti-HIV activity by using the IIIB strain for HIV-1 and the ROD strain for HIV-2 in human Tlymphocyte (MT-4) cells, and the results are sum- marized in Table 1 . Cytotoxicity induced by these compounds was also measured in MT-4 cells parallel with the antiviral activity. The results are summarized in Table 1 , in which the data for Nevirapine (BOE/BIRG587) [36] are included for comparison purposes. None of the new benthiazoles derivatives were found to inhibit HIV-1 and HIV-2 replication in vitro at EC 50 lower than the CC 50 in comparison to Nevirapine. In conclusion, the reported data showed no selective anti-HIV activity.
Conclusion
In summary, in vitro screening led to the identifi-
as new antitumor candidates, which are promising agents for further structural modification and pharmacological evaluation.
Experimental Section
General
Melting points are uncorrected and were measured on a Büchi melting point apparatus B-545 (Büchi Labortechnik AG, Switzerland). Microanalytical data were obtained with a Euro Vector EA 3000 Elemental apparatus. NMR spectra were recorded on 300 MHz ( 1 H) spectrometers with TMS as internal standard and on 75 MHz ( 13 C) spectrometers (Bruker, Germany) with TMS as internal standard and on the δ scale in ppm. Mass spectra were recorded at 70 eV on EI (Shimadzu QP5050A). Silica gel (0.040 -0.063 mm) used for column chromatography and analytical silica gel TLC plates 60 F 254 were purchased from Merck.
General procedure for the preparation of N-[2-(4-(benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]benzamides 4a -l
Method A. (Synthesis of 4a -c, l). To a cold solution of 2 (400 mg, 1.50 mmol) in dry MeCN (25 mL) was added the appropriate carboxylic acid 3a -c, l (1.50 mmol) followed by the addition of HOBt (1.50 mmol) and DCC (1.50 mmol). The mixture was stirred at 0 • C for 1 h, at 5 • C for 1 h, and then at 23 • C for 16 h. The mixture was filtered to remove DCU, and the filtrate was evaporated to dryness. The residue was partitioned successively between EtOAc and 5 % NaHCO 3 , 1 M HCl and water. The organic layer was dried (Na 2 SO 4 ), filtered and evaporate to dryness. The residue was purified by thin-layer chromatography, using CHCl 3 -MeOH (9 : 1) as eluent to give the desired product.
Method B. (Synthesis of 4d -k).
To a solution of 2 (400 mg, 1.50 mmol) in CHCl 3 (50 mL) was added the appropriate carboxylic chloride 3 (1.50 mmol) followed by a few drops of Et 3 N, and the mixture was stirred at 23 • C for 24 h. The mixture was partitioned with water (50 mL), and the organic layer was dried (Na 2 SO 4 ), filtered and evaporated to dryness. The residue was purified by TLC, using CHCl 3 -MeOH (9 : 1) as eluent, to give the pure product. Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl] 
N-[2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]-benzamide (4a)
N-[2-(4-(
N-[2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]-2-ethoxybenzamide (4d)
From 3d (
N-[2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]thiophen-2-carboxamide (4f)
From 3f (
N-[2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]-furan-2-carboxamide (4g)
From 3g (
N-[2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]-pyrrolidin-1-carboxamide (4h)
From 3h (204 mg 
N-[2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]-piperidin-1-carboxamide (4i)
From 3i (221 mg). Yield: 278 mg (90 %), m. p. 119 -122 • C (dec.), colorless powder. 13 (m, 12H, piperazine-H + piperidin-H -2-yl-piperazin-1-yl) acetic acid hydrazide (6) A mixture of 5 (3.20 g, 10.0 mmol) and hydrazine hydrate (5.0 g, 10 mmol) in EtOH (25 mL) was heated under reflux for 8 h. On cooling, the solid hydrazide 6 was collected and recrystallized from EtOH (2.58 g, 84 %), m. p. 187 -189 • C (dec.), yellow powder. 
N-[2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]-4-methyl-piperazin-1-carboxamide (4k)
From
N-[2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]-3-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-ylthio)propanamide (4l)
From 3-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-ylthio) propanoic
Preparation of (4-benzothiazol
General procedure for the preparation of 2-[4-(1,3-benzothiazol-2-yl)piperazin-1-yl]-N -(arylsulfonyl)acetohydrazides 8a -i
A solution of 6 (1.0 mmol) and arylsulfonyl chlorides 7 (1.0 mmol) in CHCl 3 (50 mL) containing Et 3 N (0.1 mL, 1.0 mmol) was stirred at 23 • C for 22 h. The solvent was evaporated to dryness, and the residue was purified by thin layer chromatography, using CHCl 3 -MeOH (15 : 1) as eluent to give the desired product which was purified by recrystallization from EtOH. 
2-[4-(1,3-Benzothiazol-2-yl)piperazin-1-yl]-N -[(4-methylphenyl)sulfonyl]acetohydrazide (8a)
2-[4-(1,3-Benzothiazol-2-yl)piperazin-1-yl]-N -[(4-methoxyphenyl)sulfonyl]acetohydrazide (8b)
2-[4-(1,3-Benzothiazol-2-yl)piperazin-1-yl]-N -[(2,5-dichlorophenyl)sulfonyl]acetohydrazide (7d)
2-[4-(1,3-Benzothiazol-2-yl)piperazin-1-yl]-N -[(quinolin-8-yl)sulfonyl]acetohydrazide (8f)
General procedure for the preparation of 1-[2-(4-(benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]-3-arylthioureas 9a -c
To a stirred solution of 2 (400 mg, 1.50 mmol) in MeCN (15 mL) was added aryl isothiocyanate (1.63 mmol), and the mixture was heated under reflux for 6 h. The precipitate was filtered and then washed with ether to give a crude product.
This was purified by column chromatography (SiO 2 ) using CHCl 3 -MeOH (19 : 1) as eluent to give the desired thiourea derivatives. Benzothiazol-2-yl)piperazin-1-yl) 
1-[2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]-3-phenylthiourea (9a)
1-[2-(4-(Benzothiazol-2-yl)piperazin-1-yl)-2-oxoethyl]3-(4-chlorophenyl)-thiourea (9b)
1-[2-(4-(
Cytotoxicity assays
Cell cultures were seeded at 1×10 5 cells mL −1 in 96 multiwall plates in specific media supplemented (5 %) with 10 % FCS and antibiotics, then incubated at 37 • C in a humidified CO 2 atmosphere in the absence or presence of serial dilutions of test compounds. Cell viability was determined after 96 h at 37 • C by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method. Compounds were dissolved in DMSO at 100 mM and then diluted into the culture medium.
